第一财经·2025-12-30 12:21Core Viewpoint - The article discusses the competitive landscape of the weight loss drug market, highlighting the significant price reductions expected with the inclusion of Eli Lilly's drug, tirzepatide, into the medical insurance system, which is anticipated to lead to a price drop of up to 80% [4][6]. Group 1: Market Dynamics - The weight loss drug market is experiencing intense competition, with multinational companies engaging in a "price war" as they seek to capture market share [3]. - Tirzepatide's price will be significantly reduced starting January 1, with specific prices listed for various dosages, indicating a shift towards more affordable options for consumers [4][5]. - Novo Nordisk's weight loss drug, semaglutide, is also expected to see a price reduction of nearly 50%, further intensifying the competitive pricing environment [6]. Group 2: Consumer Behavior - The decision-making process for patients has shifted from post-consultation to pre-consultation, with many seeking prescriptions for weight loss drugs before visiting healthcare providers [8]. - The market for weight loss drugs is becoming increasingly consumer-driven, with patients actively seeking these medications, akin to purchasing consumer electronics [9]. - Data from e-commerce platforms indicate a significant gender and age disparity in the consumer base, with women making up about three times the number of male users and 85% of buyers being under 40 years old [10]. Group 3: Future Outlook - The global weight loss drug market is projected to grow to approximately $150 billion over the next decade, indicating a trend towards these medications becoming a part of everyday lifestyle choices [10]. - The potential for direct-to-consumer sales of weight loss drugs raises concerns about safety and regulation, as bypassing traditional healthcare systems could lead to risks associated with side effects and long-term health implications [10].